NCT07552272Not yet recruiting
Hummingbird ICE Study
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The goals of this observational study are to collect data and ultrasound images using the Philips VeriSight Pro intracardiac echocardiography (ICE) catheter to assess safety and effectiveness and to support development efforts of the VeriSight Pro imaging platform.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2031
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Diseases
- Atrial fibrillation
- NCT number
- NCT07552272
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Sept 2026 to the primary completion date, Sept 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease
Other
- Contraindicated for ICE catheter placement or considerations that make placement of VeriSight not technically feasible
- Pregnancy
Who the study is looking for
- 18 years of age
- Willing to provide written, dated and signed, informed consent
- Undergoing percutaneous cardiac intervention procedures in with VeriSight Pro is used
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.